Last reviewed · How we verify
NCT05423340: CRoFT
Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
NA trial testing E-cigarette Flavor in Electronic Cigarette Use in 163 participants. Completed in 3 October 2024.
3 October 2024
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 163 |
| Start date | 12 June 2022 |
| Primary completion | 3 October 2024 |
| Estimated completion | 3 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- E-cigarette Flavor
- Tobacco Free Nicotine Pouch
Conditions studied
- Electronic Cigarette Use — all drugs for Electronic Cigarette Use →
Sponsor
Roswell Park Cancer Institute
Who can join
Adults 21 to 55, any sex, with Electronic Cigarette Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05423340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of E-cigarette Flavor
Trials testing the same drug.
- NCT04009850 — Impact of Cigarette and E-cigarette Flavors on Adult Smoking Behavior · NA · terminated
Other recruiting trials for Electronic Cigarette Use
Currently open trials in the same condition.
- NCT06609109 — Effect of Cannabis on E-Cigarette Use Behavior · Phase 1 · recruiting
- NCT06610838 — Effects of E-cigarette Use on Health · recruiting
- NCT04907136 — Developing and Testing Health Warning Labels on the ENDS Device · NA · recruiting
- NCT06142877 — Effects of Social Media Use on Young Adults' E-Cigarette Use · NA · recruiting
- NCT05338801 — Effect of Menthol on ENDS Users' Addiction and Exposure · NA · recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05423340 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05423340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing